UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of [18 F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18 F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

The lancet oncology, 2014-12, Vol.15 (13), p.1493-1502

2014

Volltextzugriff (PDF)

Markers of Recurrence and Long-Term Morbidity in Craniopharyngioma: A Systematic Analysis of 171 Patients

The journal of clinical endocrinology and metabolism, 2012-04, Vol.97 (4), p.1258-1267

2012

Volltextzugriff (PDF)

Brain dynamic neurochemical changes in dystonic patients: A magnetic resonance spectroscopy study

Movement disorders, 2013-02, Vol.28 (2), p.201-209

2013

Volltextzugriff (PDF)

Polymorphism in the Microglial Cell-Mobilizing CX3CR1 Gene Is Associated With Survival in Patients With Glioblastoma

Journal of clinical oncology, 2008-12, Vol.26 (36), p.5957-5964

2008

Volltextzugriff (PDF)

Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: Results from a prospective study

Urologic oncology, 2013-05, Vol.31 (4), p.448-454

2013

Volltextzugriff (PDF)

L-Carnitine Treatment in Incident Hemodialysis Patients: The Multicenter, Randomized, Double-Blinded, Placebo-Controlled CARNIDIAL trial

Clinical journal of the American Society of Nephrology, 2012-11, Vol.7 (11), p.1836-1842

2012

Volltextzugriff (PDF)

Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients

Current medical research and opinion, 2019-03, Vol.35 (3), p.535-542

2019

Volltextzugriff (PDF)

Validation of a short food frequency questionnaire to evaluate nutritional lifestyles in hypercholesterolemic patients

Annales d'endocrinologie, 2012-12, Vol.73 (6), p.523-529

2012

Volltextzugriff (PDF)

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.545-555

2023

Volltextzugriff (PDF)

Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial

Diabetes, obesity & metabolism, 2022-12, Vol.24 (12), p.2364-2372

2022

Volltextzugriff (PDF)

Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial

Diabetes research and clinical practice, 2020-05, Vol.163, p.108148-108148, Article 108148

2020

Volltextzugriff (PDF)

Haplotypic or genotypic combinations of three protein Z polymorphisms influence protein Z plasma level

Thrombosis and haemostasis, 2009-01, Vol.101 (1), p.212-214

2009

Volltextzugriff (PDF)

Rare genotypes of protein Z gene are a risk factor for premature myocardial infarction but not protein Z plasma level

Thrombosis and haemostasis, 2009-07, Vol.102 (1), p.131-136

2009

Volltextzugriff (PDF)

Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control

Journal of diabetes and its complications, 2021-04, Vol.35 (4), p.107831-107831, Article 107831

2021

Volltextzugriff (PDF)

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib

Journal of comparative effectiveness research, 2018-09, Vol.7 (9), p.855-865

2018

Volltextzugriff (PDF)

C ontinuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ ml versus insulin degludec 100 units/ ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Diabetes, obesity & metabolism, 2023-02, Vol.25 (2), p.545-555

2023

Volltextzugriff (PDF)

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

Diabetes, obesity & metabolism, 2023-01, Vol.25 (1), p.68-77

2023

Volltextzugriff (PDF)

743-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM) and Renal Impairment (RI): A Subgroup Analysis of the ATOS Study

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

194-OR: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Older Adults (≥70 Years) with Type 2 Diabetes (T2DM): A Subgroup Analysis of the ATOS Study

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

745-P: Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial

Diabetes, obesity & metabolism, 2021-06, Vol.23 (6), p.1221-1231

2021

Volltextzugriff (PDF)

260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

813-P: Treatment Satisfaction and Health Status in People with T2D Treated with Insulin Glargine 300 U/mL (Gla-300) : Patient-Reported Outcomes (PRO) from ATOS Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

Oncology, 2018-01, Vol.94 (1), p.55-64

2018

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(84)
Französisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Use of [18 F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18 F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

Markers of Recurrence and Long-Term Morbidity in Craniopharyngioma: A Systematic Analysis of 171 Patients

Brain dynamic neurochemical changes in dystonic patients: A magnetic resonance spectroscopy study

Polymorphism in the Microglial Cell-Mobilizing CX3CR1 Gene Is Associated With Survival in Patients With Glioblastoma

Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: Results from a prospective study

L-Carnitine Treatment in Incident Hemodialysis Patients: The Multicenter, Randomized, Double-Blinded, Placebo-Controlled CARNIDIAL trial

Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients

Validation of a short food frequency questionnaire to evaluate nutritional lifestyles in hypercholesterolemic patients

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial

Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial

Haplotypic or genotypic combinations of three protein Z polymorphisms influence protein Z plasma level

Rare genotypes of protein Z gene are a risk factor for premature myocardial infarction but not protein Z plasma level

Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib

C ontinuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ ml versus insulin degludec 100 units/ ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

743-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM) and Renal Impairment (RI): A Subgroup Analysis of the ATOS Study

194-OR: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Older Adults (≥70 Years) with Type 2 Diabetes (T2DM): A Subgroup Analysis of the ATOS Study

745-P: Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naïve People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial

260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study

813-P: Treatment Satisfaction and Health Status in People with T2D Treated with Insulin Glargine 300 U/mL (Gla-300) : Patient-Reported Outcomes (PRO) from ATOS Study

1028-P: Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naïve Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

Suchergebnisse filtern